You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Do investors value the FDA orphan drug designation?
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, June 2017
|
| DOI | 10.1186/s13023-017-0665-6 |
| Pubmed ID | |
| Authors |
Kathleen L. Miller |
| Abstract |
The Orphan Drug Act is an important piece of legislation that uses financial incentives to encourage the development of drugs that treat rare diseases. This analysis studies the effects of a portion of the Orphan Drug Act, the orphan drug designation. Specifically, it studies the value that investors place on the orphan drug designation, by investigating how investors react to companies' announcing that their product has received the designation. The results, on average, show that the stock price of a company increases by 3.36% after the announcement of the designation, increasing the value of the company. The results are more pronounced for oncology drugs, and drugs being developed by the smallest companies. The orphan designation appears to be successful at generating positive value for companies, as seen by the positive and significant average increases in stock price. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 18% |
| Canada | 1 | 9% |
| Unknown | 8 | 73% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 91% |
| Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 80 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 18% |
| Student > Ph. D. Student | 11 | 14% |
| Researcher | 10 | 13% |
| Student > Bachelor | 8 | 10% |
| Student > Doctoral Student | 5 | 6% |
| Other | 12 | 15% |
| Unknown | 20 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Business, Management and Accounting | 8 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Medicine and Dentistry | 7 | 9% |
| Economics, Econometrics and Finance | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Other | 23 | 29% |
| Unknown | 22 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2024.
All research outputs
#1,617,143
of 25,342,911 outputs
Outputs from Orphanet Journal of Rare Diseases
#172
of 3,066 outputs
Outputs of similar age
#31,036
of 323,056 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#5
of 43 outputs
Altmetric has tracked 25,342,911 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,066 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,056 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.